Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study

The Lancet Infectious Diseases

Volumn 17, Issue 4, 2017, Pages 451-458

  Irvine, Michael A ^a   Stolk, Wilma A ^c   Smith, Morgan E ^d   Subramanian, Swaminathan ^e   Singh, Brajendra K ^d   Weil, Gary J ^f   Michael, Edwin ^d   Hollingsworth, T Deirdre ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF NOTRE DAME   (United States)

^e INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; IVERMECTIN; ANTHELMINTIC AGENT; ANTIFILARIAL AGENT; ANTIPARASITIC AGENT;

ARTICLE; DISEASE ELIMINATION; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LYMPHATIC FILARIASIS; MICROFILARIA (NEMATODE LARVA); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; ANIMAL; COMBINATION DRUG THERAPY; GLOBAL HEALTH; PARASITOLOGY; PROCEDURES; STATISTICAL MODEL; TRANSMISSION;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ANTIPARASITIC AGENTS; DIETHYLCARBAMAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELEPHANTIASIS, FILARIAL; FILARICIDES; GLOBAL HEALTH; HUMANS; IVERMECTIN; MODELS, STATISTICAL;

EID: 85010685418     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30467-4     Document Type: Article

References (24)

1. 1 Rebollo, MP, Bockarie, MJ, Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame. Exp Rev Anti Infect Ther 11 (2013), 723–731.
2. 2 Molyneux, D, Zagaria, N, Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol 96 (2002), 15–40.
3. 3 Ramaiah, K, Ottesen, EA, Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis, 8, 2014, e3319.
4. 4 Hooper, PJ, Chu, BK, Mikhailov, A, Ottesen, EA, Bradley, M, Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis. PLoS Negl Trop Dis, 8, 2014, e3333.
5. 5 Ottesen, E, Duke, B, Karam, M, Behbehani, K, Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ, 75, 1997, 491.
6. 6 Ottesen, EA, Hooper, PJ, Bradley, M, Biswas, G, The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis, 2, 2008, e317.
7. 7 Turner, HC, Bettis, AA, Chu, BK, et al. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014). Infect Dis Poverty, 5, 2016, 54.
8. 8 WHO. Global programme to eliminate lymphatic filariasis: progress report, 2014. Wkly Epidemiol Rec 38 (2014), 489–504.
9. 9 Plaisier, A, Stolk, W, Van Oortmarssen, G, Habbema, J, Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection. Parasitol Today 16 (2000), 298–302.
10. 10 Ramaiah, K, Das, P, Appavoo, N, et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 5 (2000), 842–847.
11. 11 Krentel, A, Fischer, PU, Weil, GJ, A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis, 7, 2013, e2447.
12. 12 Kumar, A, Kumar, P, Nagaraj, K, Nayak, D, Ashok, L, Ashok, K, A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India. J Vector Borne Dis, 46, 2009, 237.
13. 13 Thomsen, EK, Sanuku, N, Baea, M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 62 (2016), 334–341.
14. 14 El Setouhy, M, Ramzy, RM, Ahmed, ES, et al. A randomized clinical trial comparing single-and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am J Trop Med Hyg 70 (2004), 191–196.
15. 15 Irvine, MA, Reimer, LJ, Njenga, SM, et al. Modelling strategies to break transmission of lymphatic filariasis-aggregation, adherence and vector competence greatly alter elimination. Parasit Vector 8 (2015), 1–19.
16. 16 Stolk, WA, De Vlas, SJ, Borsboom, GJ, Habbema, JDF, LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology 135 (2008), 1583–1598.
17. 17 Chan, M-S, Srividya, A, Norman, R, et al. Epifil: a dynamic model of infection and disease in lymphatic filariasis. Am J Trop Med Hyg 59 (1998), 606–614.
18. 18 Subramanian, S, Stolk, W, Ramaiah, K, et al. The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India. Parasitology 128 (2004), 467–482.
19. 19 Singh, BK, Michael, E, Bayesian calibration of simulation models for supporting management of the elimination of the macroparasitic disease, lymphatic filariasis. Parasit Vector 8 (2015), 1–26.
20. 20 Jambulingam, P, Subramanian, S, de Vlas, S, Vinubala, C, Stolk, W, Mathematical modelling of lymphatic filariasis elimination programs in India: required duration of mass drug administration and post-treatment level of infection indicators. Parasit Vector, 9, 2016, 501.
21. 21 Singh, BK, Bockarie, MJ, Gambhir, M, et al. Sequential modelling of the effects of mass drug treatments on anopheline-mediated lymphatic filariasis infection in Papua New Guinea. PLoS One, 8, 2013, e67004.
22. 22 Gambhir, M, Bockarie, M, Tisch, D, et al. Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol, 8, 2010, 22.
23. 23 Michael, E, Singh, BK, Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis. BMC Med, 14, 2016, 14.
24. 24 Babu, B, Kar, SK, Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9 (2004), 702–709.